Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02301143 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)
A Phase 2 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 107
- Enrollment target
NCT02301143 is a Phase 2 study that has completed, run by Celgene. The registered enrollment target is 107 participants.
The verdict
NCT02301143, a Phase 2 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 107 participants
- Enrollment target
Study Summary
This clinical study is in subjects who are 18 years old or older with locally advanced pancreatic cancer who have not received prior treatment for their pancreatic cancer. The study treats all subjects with nab-Paclitaxel plus gemcitabine for approximately 6 months of treatment. Subjects who complete the treatment will choose, with their treating physicians, what additional treatment should be given: more nab-Paclitaxel plus gemcitabine, Chemoradiation therapy, or surgery to treat the locally advanced pancreatic cancer.
Interventions
- DRUG Capecitabine
- DRUG Gemcitabine
- PROCEDURE Surgery
- DRUG nab-Paclitaxel
- DRUG Chemoradiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2015-04-21 |
| Est. Completion | 2018-04-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02301143
The ClinicalTrials.gov registry entry for NCT02301143 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Capecitabine is the first listed.
NCT02301143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02301143 about?
NCT02301143 is a clinical study titled "Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)". This clinical study is in subjects who are 18 years old or older with locally advanced pancreatic cancer who have not received prior treatment for their pancreatic cancer. The study treats all subjects with nab-Paclitaxel plus gemcitabine for approximately 6 months of treatment. Subjects who complet...
What is the current status of trial NCT02301143?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2015-04-21. Estimated completion is 2018-04-26.
What interventions are being tested in trial NCT02301143?
The interventions under investigation include: Capecitabine (DRUG), Gemcitabine (DRUG), Surgery (PROCEDURE), nab-Paclitaxel (DRUG), Chemoradiation (DRUG).
Who is sponsoring clinical trial NCT02301143?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.